Vorozole

Vorozole
Clinical data
Other names	R-76713; Rizivor
ATC code	L02BG05 (WHO) ;
Pharmacokinetic data
Bioavailability	Very high
Metabolism	Hepatic
Elimination half-life	8 hours
Identifiers
	IUPAC name 6-[(4-Chlorophenyl)(1,2,4-triazol-1-yl)methyl]-1-methylbenzotriazole;
CAS Number	129731-10-8 ;
PubChem CID	6918191;
ChemSpider	5293402 ;
UNII	1E2S9YXV2A;
KEGG	D03786 ;
ChEMBL	ChEMBL224060 ;
CompTox Dashboard (EPA)	DTXSID20156230 ;
Chemical and physical data
Formula	C16H13ClN6
Molar mass	324.77 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Clc1ccc(cc1)[C@@H](c2ccc3nnn(c3c2)C)n4ncnc4;
	(what is this?) (verify)

Vorozole (developmental code name R-76713; former tentative brand name Rizivor) is a triazole based competitive inhibitor of the aromatase enzyme. It underwent clinical testing for evaluation for use as an antineoplastic agent; however it was withdrawn from testing when no difference was detected in the duration of median survival as compared to the progestational agent megestrol acetate and research instead focused on the other third generation aromatase inhibitors anastrozole, letrozole and exemestane.^[1]

References

^ Goss PE (1998). "Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor" (PDF). Breast Cancer Research and Treatment. 49. 49 (Suppl 1): S59-65, discussion S73-7. doi:10.1023/a:1006052923468. PMID 9797019. S2CID 28231447.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

[pmid9797019-1] Goss PE (1998). "Pre-clinical and clinical review of vorozole, a new third generation aromatase inhibitor" (PDF). Breast Cancer Research and Treatment. 49. 49 (Suppl 1): S59-65, discussion S73-7. doi:10.1023/a:1006052923468. PMID 9797019. S2CID 28231447.

[1]